Related Experiment Video
Updated: Jun 24, 2025

Colorectal Cancer Cell Surface Protein Profiling Using an Antibody Microarray and Fluorescence Multiplexing
Published on: September 25, 2011
Multiplexed Profiling of CDK Kinase Activities in Tumor Biopsies with Fluorescent Peptide Biosensors
Chloé Royet1, Sébastien Diot1, Mélanie Onofre1
1Institut des Biomolécules Max Mousseron, CNRS, UMR 5247, Montpellier University, 1919 Route de Mende, 34293 Montpellier, France.
Abstract:
Detection of disease biomarkers constitutes a major challenge for the development of personalized and predictive diagnostics as well as companion assays. Protein kinases (PKs) involved in the coordination of cell cycle progression and proliferation that are hyperactivated in human cancers constitute attractive pharmacological targets and relevant biomarkers. Although it is relatively straightforward to assess the relative abundance of PKs in a biological sample, there is not always a direct correlation with enzymatic activity, which is regulated by several posttranslational mechanisms. Studies of relative abundance therefore convey limited information, and the lack of selective, sensitive, and standardized tools together with the inherent complexity of biological samples makes it difficult to quantify PK activities in physio-pathological tissues. To address this challenge, we have developed a toolbox of fluorescent biosensors that report on CDK activities in a sensitive, selective, dose-dependent, and quantitative fashion, which we have implemented to profile CDK activity signatures in cancer cell lines and biopsies from human tumors. In this study, we report on a standardized and calibrated biosensing approach to quantify CDK1,2,4, and 6 activities simultaneously through a combination of four different biosensors in a panel of 40 lung adenocarcinoma and 40 follicular lymphoma samples. CDK activity profiling highlighted two major patterns which were further correlated with age, sex of patients, tumor size, grade, and genetic and immunohistochemical features of the biopsies. Multiplex CDKACT biosensing technology provides new and complementary information relative to current genetic and immunohistochemical characterization of tumor biopsies, which will be useful for diagnostic purposes, potentially guiding therapeutic decision. These fluorescent peptide biosensors offer promise for personalized diagnostics based on kinase activity profiling.
Insights
We developed fluorescent biosensors to measure protein kinase (PK) activity, crucial for cancer diagnostics. This kinase activity profiling offers new insights beyond traditional methods, aiding personalized medicine and therapeutic decisions.
Area of Science:
- Biochemistry and Molecular Biology
- Cancer Research
- Biomedical Diagnostics
Background:
- Protein kinases (PKs) are key regulators of cell proliferation and are implicated in cancer.
- Quantifying PK enzymatic activity is challenging due to post-translational modifications and biological sample complexity.
- Current methods for assessing PKs often focus on abundance, not activity, limiting diagnostic utility.
Purpose of the Study:
- To develop and validate a toolbox of fluorescent biosensors for sensitive and quantitative measurement of PK activities.
- To profile Cyclin-Dependent Kinase (CDK) activity signatures in human cancer biopsies.
- To explore the correlation of CDK activity patterns with clinical and pathological features.
Main Methods:
- Development of a toolbox of selective and sensitive fluorescent peptide biosensors.
- Standardized and calibrated biosensing approach to simultaneously quantify CDK1, 2, 4, and 6 activities.
- Application of multiplex CDK activity (CDKACT) biosensing in lung adenocarcinoma and follicular lymphoma patient samples.
Main Results:
- Successfully quantified simultaneous activities of CDK1, 2, 4, and 6 using four distinct biosensors.
- Identified two major CDK activity patterns in tumor samples.
- Correlated these activity patterns with patient age, sex, tumor size, grade, and molecular features.
Conclusions:
- Multiplex CDKACT biosensing provides complementary information to genetic and immunohistochemical analyses.
- This technology offers potential for improved diagnostic purposes and guiding therapeutic decisions in oncology.
- Fluorescent peptide biosensors show promise for personalized diagnostics through kinase activity profiling.
More Related Videos
09:52DNA-barcode-based Multiplex Immunofluorescence Imaging to Analyze FFPE Specimens from Genetically Reprogrammed Murine Melanoma
Published on: June 6, 2025
10:49Automated Multiplex Immunofluorescence Panel for Immuno-oncology Studies on Formalin-fixed Carcinoma Tissue Specimens
Published on: January 21, 2019